Further, the mode of addition of disintegrants on EFV dissolution from tablets containing 600 mg of the drug was evaluated by incorporating the disintegrants extragranularly (EG), intragranularly (IG) or distributing them equally (IG and EG). In vitro dissolution of the prepared tablets was conducted using the recommended medium and a
dissolution medium developed in-house, which had the ability to discriminate between the formulations.
The t(50) and t(80) values were indicative of the fact that the drug release was faster from tablet formulations containing Cl-amidine ic50 CP. CP was able to release the drug faster than the other two disintegrants in both dissolution media and the drug release was unaffected by the mode of CP addition.”
“Purpose of review
Re-transplantation of the lung has come of age. Here, we wish to review the recent literature on the topic and discuss clinical implications.
Recent findings
Many large volume transplant centres routinely perform lung re-transplantation with satisfactory outcomes.
The main indication is bronchiolitis obliterans syndrome, that is chronic rejection of a previous lung transplant. Other indications, such as primary graft failure or early airway complications, are regarded with more caution, as outcomes compare less favourably with those following primary transplantation.
Summary
Re-transplantation Z-VAD-FMK inhibitor of the lung can be performed safely
and with outcomes rivalling those of primary transplants in carefully selected recipients with chronic rejection of a previous transplant.”
“Purpose of review
Lung transplant continues to be hampered by see more the number of available donors. Ex-vivo lung perfusion (EVLP) has emerged as an essential tool for the reassessment, under a controlled scenario, of lungs that initially did not meet transplantation criteria. The purpose of the current study is to review the most recent clinical and research reports and summarize their findings.
Recent findings
Several centers have presented positive data when using ex-vivo perfusion to identify better grafts from the higher risk donor pool. The posttransplant results, when using these organs, are not significantly different from those obtained when using standard criteria donors. In addition, a great amount of research reports have emphasized the potential of ex-vivo perfusion as a platform in reducing the injurious effects of ischemia-reperfusion.
Summary
EVLP has already proved its value as a tool to identify ‘good’ lungs from the previously rejected pool. But as new therapeutics arise, EVLP will also prove its value as a reproducible platform for their evaluation.